BACKGROUND: Patients experience multiple sclerosis (MS) differently based on their disease type and other factors. This study aimed to explore the relative importance that patients with MS place on various attributes of MS drug therapies and to elucidate these patients' preferences regarding treatment characteristics such as administration, potential benefits, and side effects of the therapies. METHODS: Focus groups were conducted in Vancouver, Canada, with 23 adult patients with MS. Participants were interviewed in three groups based on disease category and MS treatment experience: treatment-naive, non-treatment-naive relapsing-remitting and non-treatment-naive progressive MS. RESULTS: Overall, the most important characteristics of MS drugs were effectiveness and side effects. As such, there is hesitancy about trying new-to-market drugs because the risks, benefits, and costs may not be well known. Participants valued stability in their treatment and generally did not want to take on the additional risk of trying a new drug if they felt that their current medication was providing benefit. Convenience and method of administration were secondary considerations that would generally be valued only if expected risks and benefits were considered equal or superior. CONCLUSIONS: This qualitative study shows that patients consider the impact and likelihood of benefits and side effects first and foremost when making drug treatment decisions and that other factors, such as convenience and method of administration, are of secondary concern.
BACKGROUND: Patients experience multiple sclerosis (MS) differently based on their disease type and other factors. This study aimed to explore the relative importance that patients with MS place on various attributes of MS drug therapies and to elucidate these patients' preferences regarding treatment characteristics such as administration, potential benefits, and side effects of the therapies. METHODS: Focus groups were conducted in Vancouver, Canada, with 23 adult patients with MS. Participants were interviewed in three groups based on disease category and MS treatment experience: treatment-naive, non-treatment-naive relapsing-remitting and non-treatment-naive progressive MS. RESULTS: Overall, the most important characteristics of MS drugs were effectiveness and side effects. As such, there is hesitancy about trying new-to-market drugs because the risks, benefits, and costs may not be well known. Participants valued stability in their treatment and generally did not want to take on the additional risk of trying a new drug if they felt that their current medication was providing benefit. Convenience and method of administration were secondary considerations that would generally be valued only if expected risks and benefits were considered equal or superior. CONCLUSIONS: This qualitative study shows that patients consider the impact and likelihood of benefits and side effects first and foremost when making drug treatment decisions and that other factors, such as convenience and method of administration, are of secondary concern.
Entities:
Keywords:
Drug treatment; Multiple sclerosis; Patient perspective; Patient preference; Qualitative study
Authors: Larry D Lynd; Anthony Traboulsee; Carlo A Marra; Nicole Mittmann; Charity Evans; Kathy H Li; Melanie Carter; Celestin Hategekimana Journal: Ther Adv Neurol Disord Date: 2016-05-15 Impact factor: 6.570
Authors: Leslie S Wilson; Aimee Loucks; Gregory Gipson; Lixian Zhong; Christine Bui; Elizabeth Miller; Mary Owen; Daniel Pelletier; Douglas Goodin; Emmanuelle Waubant; Charles E McCulloch Journal: Int J MS Care Date: 2015 Mar-Apr
Authors: Joanna Coast; Hareth Al-Janabi; Eileen J Sutton; Susan A Horrocks; A Jane Vosper; Dawn R Swancutt; Terry N Flynn Journal: Health Econ Date: 2011-05-06 Impact factor: 3.046
Authors: Kathrin S Utz; Jana Hoog; Andreas Wentrup; Sebastian Berg; Alexandra Lämmer; Britta Jainsch; Anne Waschbisch; De-Hyung Lee; Ralf A Linker; Thomas Schenk Journal: Ther Adv Neurol Disord Date: 2014-11 Impact factor: 6.570
Authors: F Reed Johnson; George Van Houtven; Semra Ozdemir; Steve Hass; Jeff White; Gordon Francis; David W Miller; J Theodore Phillips Journal: J Neurol Date: 2009-04-27 Impact factor: 4.849
Authors: Patrick Vermersch; Thomas Berger; Ralf Gold; Carsten Lukas; Alex Rovira; Bianca Meesen; Declan Chard; Manuel Comabella; Jacqueline Palace; Maria Trojano Journal: Mult Scler Date: 2016-08 Impact factor: 6.312
Authors: Jane Desborough; Crystal Brunoro; Anne Parkinson; Katrina Chisholm; Mark Elisha; Janet Drew; Vanessa Fanning; Christian Lueck; Anne Bruestle; Matthew Cook; Hanna Suominen; Antonio Tricoli; Adam Henschke; Christine Phillips Journal: Health Expect Date: 2020-06-24 Impact factor: 3.377
Authors: Hiba El Masri; Treasure M McGuire; Christine Dalais; Mieke van Driel; Helen Benham; Samantha A Hollingworth Journal: J Med Libr Assoc Date: 2022-04-01